Boehringer Ingelheim, which has spent over $350 million this year to bolster its US operations, is investing $65 million on an early-stage R&D site.
The 72,000 square-foot facility at the company’s US headquarters in Ridgefield, Connecticut will handle production of active pharmaceutical ingredients used in early development activities. If successful, they will move on to the firm’s full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.
Boehringer has been splashing the cash this year and in August, the company started work on a $42 million new drug safety assessment building also at Ridgefield. Other projects have included a $100 million expansion of its biological manufacturing facility in Missouri, while in September, its Roxane generics unit opened a $50 million high containment operations facility in Columbus, Ohio “in order to meet a growing market demand for high potency and oncology products”.
In addition, Boehringer bought Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California in March for an undisclosed sum. Martin Carroll, chief executive of Boehringer in the USA, said “these are exciting projects, ones that increase [the company’s] R&D capabilities and reinforce our commitment to growth and innovation in the USA”.
